Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.
Katie Eder, Senior Editor, Pharmacy Times
Advertisement
Articles by Katie Eder, Senior Editor, Pharmacy Times
Advertisement
Latest Updated Articles
Diabetes Drug Label Includes New RisksPublished: December 8th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
3
FDA Updates Boxed Warning for Cilta-Cel Following Reports of Immune Effector Cell–Associated Enterocolitis
4
Medetomidine: The Demon in the Illicit Fentanyl Supply
5
